Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Emergent BioSolutions Inc. EBS
$8.87
-$1.39 (-15.65%)
На 18:00, 12 мая 2023
+480.61%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
539766864.00000000
-
week52high
40.45
-
week52low
7.74
-
Revenue
1120900000
-
P/E TTM
-2
-
Beta
0.93321700
-
EPS
-4.25000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 20:00
Описание компании
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | Equal-Weight | 04 мая 2022 г. |
| Chardan Capital | Buy | Buy | 29 апр 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 10 мар 2022 г. |
| Chardan Capital | Buy | Buy | 10 ноя 2021 г. |
| Benchmark | Hold | Buy | 08 ноя 2021 г. |
| Cowen & Co. | Market Perform | Market Perform | 12 сент 2022 г. |
| Benchmark | Hold | Buy | 10 ноя 2022 г. |
| Chardan Capital | Buy | Buy | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fox Jennifer Lynne | A | 88391 | 42135 | 09 дек 2022 г. |
| Fox Jennifer Lynne | A | 46256 | 14045 | 09 дек 2022 г. |
| Glessner Coleen | A | 108136 | 72232 | 09 дек 2022 г. |
| Glessner Coleen | A | 35904 | 24078 | 09 дек 2022 г. |
| Richard Ronald | D | 19837 | 1912 | 25 ноя 2022 г. |
| Fox Jennifer Lynne | D | 32211 | 416 | 11 ноя 2022 г. |
| Dayal Sujata Tyagi | A | 11852 | 11852 | 21 июл 2022 г. |
| Zoon Kathryn C | D | 19654 | 1173 | 09 июн 2022 г. |
| Harsanyi Zsolt | A | 38052 | 8446 | 26 мая 2022 г. |
| Hauer Jerome M | A | 23661 | 8446 | 26 мая 2022 г. |
Новостная лента
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
Zacks Investment Research
10 мая 2023 г. в 12:12
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Emergent BioSolutions Inc. (EBS) Q1 2023 Earnings Call Transcript
Seeking Alpha
09 мая 2023 г. в 22:40
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Paul Williams - Senior Vice President, Products Business Rich Lindahl - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald Christopher Sakai - Singular Research Operator Good day, and thank you for standing by. Welcome to the Emergent BioSolutions First Quarter 2020 Financial Results Conference Call.
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:52
Emergent Biosolutions (EBS) came out with a quarterly loss of $3.17 per share versus the Zacks Consensus Estimate of a loss of $1.67. This compares to earnings of $0.18 per share a year ago.
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
GlobeNewsWire
19 апр 2023 г. в 16:05
GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023.
Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why
Zacks Investment Research
03 апр 2023 г. в 10:39
Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.